Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT04164069
Title Dasatinib in Preventing Oxaliplatin-Induced Peripheral Neuropathy in Patients With Colorectal Cancer Receiving FOLFOX and Bevacizumab
Recruitment Recruiting
Gender both
Phase Phase I
Variant Requirements No
Sponsors Anne Noonan
Indications

colorectal cancer

Therapies

Bevacizumab + Dasatinib + Fluorouracil + Leucovorin + Oxaliplatin

Age Groups: senior | adult
Covered Countries USA


No variant requirements are available.